Smart functional nucleic acid chimeras: Enabling tissue specific RNA targeting therapy

RNA Biology

Volumn 12, Issue 4, 2015, Pages 412-425

  Aaldering, Lukas J ^a,b   Tayeb, Hossam ^c   Krishnan, Shilpa ^d   Fletcher, Susan ^e,f   Wilton, Stephen D ^e,f   Veedu, Rakesh N ^a,c,e,f  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e MURDOCH UNIVERSITY   (Australia)

^f Western Australian Biomedical Research Institute   (Australia)

Author keywords

Aptamer chimera; Aptamer targeted delivery; Aptamers; miRNA delivery; Modified nucleotides; SiRNA delivery

Indexed keywords

APTAMER; MICRORNA; NANOCARRIER; NUCLEIC ACID; OLIGONUCLEOTIDE; RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; LONG UNTRANSLATED RNA;

CHIMERA; DISULFIDE BOND; DRUG BIOAVAILABILITY; GENE SILENCING; GENE TARGETING; HUMAN; MOLECULAR BEACON; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN SECONDARY STRUCTURE; REVIEW; RNA BINDING; RNA INTERFERENCE; TARGET ORGAN; TUMOR SUPPRESSOR GENE; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; METABOLISM;

ANIMALS; APTAMERS, NUCLEOTIDE; HUMANS; ORGAN SPECIFICITY; RNA; RNA, LONG NONCODING;

EID: 84928264182     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.1080/15476286.2015.1017234     Document Type: Review

References (149)

1. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010; 9:537-50. PMID:20592747 http://dx.doi.org/10.1038/nrd3141
2. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 2007; 107:3715-43. PMID:17715981 http://dx.doi.org/10.1021/cr0306743
3. Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP. Pegaptanib, a targeted anti- VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5:123-32. PMID:16518379 http://dx.doi.org/10.1038/nrd1955
4. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249:505-10. PMID:2200121 http://dx.doi.org/10.1126/science.2200121
5. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346:818-22. PMID:1697402 http://dx.doi.org/10.1038/346818a0
6. Brown D, Gold L. Template recognition by an RNAdependent RNA polymerase: identification and characterization of two RNA binding sites on Q beta replicase. Biochemistry 1995; 34:14765-74. PMID:7578085 http://dx.doi.org/10.1021/bi00045a018
7. Klug SJ, Famulok M. All you wanted to know about SELEX. Mol Biol Rep 1994; 20:97-107. PMID:7536299 http://dx.doi.org/10.1007/BF00996358
8. Gopinath SC. Methods developed for SELEX. Anal Bioanal Chem 2007; 387:171-82. PMID:17072603
9. Stoltenburg R, Reinemann C, Strehlitz B. SELEX–a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007; 24:381-403. PMID:17627883 http://dx.doi.org/10.1016/j. bioeng.2007.06.001
10. Lauridsen LH, Shamaileh HA, Edwards SL, Taran E, Veedu RN. Rapid one-step selection method for generating nucleic acid aptamers: development of a DNA aptamer against alpha-bungarotoxin. Plos One 2012; 7:e41702. PMID:22860007 http://dx.doi.org/10.1371/journal.pone.0041702
11. Nitsche A, Kurth A, Dunkhorst A, Panke O, Sielaff H, Junge W, Muth D, Scheller F, Stöcklein W, Dahmen C, et al. One-step selection of Vaccinia virusbinding DNA aptamers by MonoLEX. BMC Biotechnol 2007; 7:48. PMID:17697378 http://dx.doi.org/ 10.1186/1472-6750-7-48
12. Peng L, Stephens BJ, Bonin K, Cubicciotti R, Guthold M. A combined atomic force/fluorescence microscopy technique to select aptamers in a single cycle froma small pool of random oligonucleotides. Microsc Res Tech 2007; 70:372-81. PMID:17262788 http://dx.doi.org/ 10.1002/jemt.20421
13. Fan M, McBurnett SR, Andrews CJ, Allman AM, Bruno JG, Kiel JL. Aptamer selection express: a novel method for rapid single-step selection and sensing of aptamers. J Biomol Tech 2008; 19:311-9. PMID:19183794
14. Dua P, Kim S, Lee DK. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011; 54:215-25. PMID:21300154 http://dx.doi.org/10.1016/j.ymeth.2011.02.002
15. Liu K, Lin B, Lan X. Aptamers: a promising tool for cancer imaging, diagnosis, and therapy. J Cell Biochem 2013; 114:250-5. PMID:22949372 http://dx. doi.org/10.1002/jcb.24373
16. Liss M, Petersen B, Wolf H, Prohaska E. An aptamerbased quartz crystal protein biosensor. Anal Chem 2002; 74:4488-95.D PMID:12236360 http://dx. doi.org/10.1021/ac011294p
17. Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol 2006; 2:711-9. PMID:17108989 http://dx.doi.org/10.1038/nchembio839
18. Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys 2013; 42:217-39. PMID:23654304 http://dx.doi.org/10.1146/annurev-biophys-083012-130404
19. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. Cell 2009; 136:642-55. PMID:19239886 http://dx.doi.org/10.1016/j. cell.2009.01.035
20. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1:347-55. PMID:12489851 http://dx.doi.org/10.4161/cbt.1.4.4
21. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5:522-31. PMID:15211354 http://dx.doi.org/10.1038/nrg1379
22. Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals 2010; 3:1761-1778.http://dx. doi.org/10.3390/ph3061761
23. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001; 276:16464-8. PMID:11279054
24. Daniels DA, Chen H, Hicke BJ, Swiderek KM, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003; 100:15416-21. PMID:14676325 http://dx.doi.org/ 10.1073/pnas.2136683100
25. Kunii T, Ogura S, Mie M, Kobatake E. Selection of DNA aptamers recognizing small cell lung cancer using living cell-SELEX. Analyst 2011; 136:1310-2. PMID:21321690
26. Ohuchi S. Cell-SELEX Technology. Biores Open Access 2012; 1:265-72. PMID:23515081
27. Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, Clary BM. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 2010; 6:22-4. PMID:19946274 http://dx.doi.org/10.1038/nchembio.277
28. Xie FY, Woodle MC, Lu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11:67-73. PMID:16478693 http://dx.doi.org/10.1016/S1359-6446(05)03668-8
29. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-8. PMID:15538359 http://dx. doi.org/10.1038/nature03121
30. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8:129-38. PMID:19180106 http://dx.doi.org/10.1038/nrd2742
31. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol 2007; 25:1149-57. PMID:17873866 http://dx.doi.org/10.1038/nbt1339
32. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31:2717-24. PMID:12771197 http://dx.doi.org/10.1093/nar/ gkg385
33. Kam NW, Liu Z, Dai H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005; 127:12492-3. PMID:16144388 http://dx.doi.org/10.1021/ja053962k
34. Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004; 32:e149. PMID:15520458
35. Zhou J, Rossi JJ. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011; 21:1-10. PMID:21182455 http://dx.doi.org/10.1089/oli.2010.0264
36. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 2000; 106:923-8. PMID:11032850 http://dx.doi.org/10.1172/JCI11324
37. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence 2010; 1:4. PMID:20226078 http://dx.doi.org/10.1186/1758-907X-1-4
38. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34:e73. PMID:16740739
39. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64:7668-72. PMID:15520166 http://dx.doi.org/10.1158/0008-5472.CAN-04-2550
40. McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24:1005-15. PMID:16823371 http://dx.doi.org/10.1038/nbt1223
41. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008; 16:1481-9. PMID:18461053 http://dx.doi.org/10.1038/mt.2008.92
42. Chavda SC, Griffin P, Han-Liu Z, Keys B, Vekony MA, Cann AJ. Molecular determinants of the V3 loop of human immunodeficiency virus type 1 glycoprotein gp120 responsible for controlling cell tropism. J Gen Virol 1994; 75: 3249-53. PMID:7964635 http://dx.doi.org/10.1099/0022-1317-75-11-3249
43. Chesebro B, Nishio J, Perryman S, Cann A, O’Brien W, Chen IS, Wehrly K. Identification of human immunodeficiency virus envelope gene sequences influencing viral entry into CD4-positive HeLa cells, T-leukemia cells, and macrophages. J Virol 1991; 65:5782-9. PMID:1920616
44. Mondor I, Moulard M, Ugolini S, Klasse PJ, Hoxie J, Amara A, Delaunay T, Wyatt R, Sodroski J, Sattentau QJ. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH- and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies. Virology 1998; 248:394-405. PMID:9721247 http://dx.doi.org/10.1006/viro.1998.9282
45. Khati M, Schuman M, Ibrahim J, Sattentau Q, Gordon S, James W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2’F-RNA aptamers. J Virol 2003; 77:12692-8. PMID:14610191 http://dx.doi.org/10.1128/JVI.77.23.12692-12698.2003
46. Chithrani BD, Chan WC. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett 2007; 7:1542-50. PMID:17465586 http://dx.doi. org/10.1021/nl070363y
47. Gao H, Shi W, Freund LB. Mechanics of receptormediated endocytosis. Proc Natl Acad Sci U S A 2005; 102:9469-74. PMID:15972807 http://dx.doi. org/10.1073/pnas.0503879102
48. Yoo H, Jung H, Kim SA, Mok H. Multivalent combtype aptamer-siRNA conjugates for efficient and selective intracellular delivery. Chem Commun 2014; 50:6765-7. PMID:24830507 http://dx.doi.org/10.1039/c4cc01620c
49. Yu C, Hu Y, Duan J, Yuan W, Wang C, Xu H, Yang XD. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. Plos One 2011; 6:e24077. PMID:21912664 http://dx.doi.org/10.1371/journal. pone.0024077
50. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville A, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37. PMID:19723653 http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
51. Walter JG, Kokpinar O, Friehs K, Stahl F, Scheper T. Systematic investigation of optimal aptamer immobilization for protein-microarray applications. Anal Chem 2008; 80:7372-8. PMID:18729475 http://dx. doi.org/10.1021/ac801081v
52. Bagalkot V, Gao X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 2011; 5:8131-9. PMID:21936502 http://dx.doi.org/10.1021/nn202772p
53. Liu HY, Gao X. A universal protein tag for delivery of SiRNA-aptamer chimeras. Sci Rep 2013; 3:3129. PMID:24196104
54. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, 2nd, Giangrande PH. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009; 27:839-49. PMID:19701187 http://dx.doi.org/10.1038/nbt.1560
55. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 2008; 8:554-65. PMID:18991566
56. Kim E, Jung Y, Choi H, Yang J, Suh JS, Huh YM, Kim K, Haam S. Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex. Biomaterials 2010; 31:4592-9. PMID:20206379 http://dx.doi. org/10.1016/j.biomaterials.2010.02.030
57. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay. Nature 2010; 465:227-30. PMID:20463739 http://dx.doi.org/10.1038/nature08999
58. Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE. Prostate-targeted radiosensitization via aptamershRNA chimeras in human tumor xenografts. J Clin Invest 2011; 121:2383-90. PMID:21555850 http:// dx.doi.org/10.1172/JCI45109
59. Thiel KW, Hernandez LI, Dassie JP, Thiel WH, Liu X, Stockdale KR, Rothman AM, Hernandez FJ, McNamara JO, 2nd, Giangrande PH. Delivery of chemo-sensitizing siRNAs to HER2C-breast cancer cells using RNA aptamers. Nucleic Acids Res 2012; 40:6319-37. PMID:22467215 http://dx.doi.org/10.1093/nar/gks294
60. Guo S, Tschammer N, Mohammed S, Guo P. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 2005; 16:1097-109. PMID:16149908
61. Khaled A, Guo S, Li F, Guo P. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 2005; 5:1797-808. PMID:16159227 http://dx.doi.org/10.1021/nl051264s
62. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z, Seung E, Deruaz M, Einarsson JI, Yang L, et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 2011; 121:2401-12. PMID:21576818 http://dx.doi.org/10.1172/JCI45876
63. Wheeler LA, Vrbanac V, Trifonova R, Brehm MA, Gilboa- Geffen A, Tanno S, Greiner DL, Luster AD, Tager AM, Lieberman J. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013; 21:1378-89. PMID:23629001 http://dx.doi.org/10.1038/mt.2013.77
64. Zhu Q, Shibata T, Kabashima T, Kai M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. Eur J Med Chem 2012; 56:396-9. PMID:22907035
65. Qiu C, Peng WK, Shi F, Zhang T. Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene. Genet Mol Res 2012; 11:3236-45. PMID:23079817
66. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R, Rossi JJ. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009; 37:3094-109. PMID:19304999 http://dx.doi.org/10.1093/nar/gkp185
67. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H, Smith DD, Swiderski P, Rossi JJ, Akkina R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(C) T cell decline in humanized mice. Sci Transl Med 2011; 3:66ra6. PMID:21248316 http://dx.doi.org/10.1126/ scitranslmed.3001581
68. Zhou J, Shu Y, Guo P, Smith DD, Rossi JJ. Dual functional RNA nanoparticles containing phi29 motor pRNA and anti-gp120 aptamer for cell-type specific delivery and HIV-1 inhibition. Methods 2011; 54:284-94. PMID:21256218 http://dx.doi.org/10.1016/j.ymeth.2010.12.039
69. Zhou J, Neff CP, Swiderski P, Li H, Smith DD, Aboellail T, Remling-Mulder L, Akkina R, Rossi JJ. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol Ther 2013; 21:192-200. PMID:23164935 http://dx.doi.org/10.1038/mt.2012.226
70. Wang CW, Chung WH, Cheng YF, Ying NW, Peck K, Chen YT, Hung SI. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. J Allergy Clin Immunol 2013; 132:713-22.e11. PMID:23791505 http://dx.doi.org/10.1016/j.jaci.2013.04.036
71. Zhao N, Bagaria HG, Wong MS, Zu Y. A nanocomplex that is both tumor cell-selective and cancer genespecific for anaplastic large cell lymphoma. J Nanobiotech 2011; 9:2. PMID:21281497 http://dx.doi.org/10.1186/1477-3155-9-2
72. Tuleuova N, An CI, Ramanculov E, Revzin A, Yokobayashi Y. Modulating endogenous gene expression of mammalian cells via RNA-small molecule interaction. Biochem Biophys Res Commun 2008; 376:169-73. PMID:18765226 http://dx.doi.org/10.1016/j.bbrc.2008.08.112
73. Beisel CL, Bayer TS, Hoff KG, Smolke CD. Modelguided design of ligand-regulated RNAi for programmable control of gene expression. Mol Syst Biol 2008; 4:224. PMID:18956013 http://dx.doi.org/10.1038/msb.2008.62
74. An CI, Trinh VB, Yokobayashi Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamersmall molecule interaction. RNA 2006; 12:710-6. PMID:16606868 http://dx.doi.org/10.1261/rna.2299306
75. Noguchi K, Ishitu Y, Takaku H. Evaluating target silencing by short hairpin RNA mediated by the group I intron in cultured mammalian cells. BMC Biotechnol 2011; 11:79. PMID:21781346 http://dx.doi.org/10.1186/1472-6750-11-79
76. Reif R, Haque F, Guo P. Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells. Nucleic Acid Ther 2012; 22:428-37. PMID:23113765
77. Wilner SE, Wengerter B, Maier K, de Lourdes Borba Magalhaes M, Del Amo DS, Pai S, Opazo F, Rizzoli SO, Yan A, Levy M. An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 2012; 1:e21.
78. Berezhnoy A, Brenneman R, Bajgelman M, Seales D, Gilboa E. Thermal Stability of siRNA Modulates Aptamer- conjugated siRNA Inhibition. Mol Ther Nucleic Acids 2012; 1:e51. PMID:23344651
79. Berezhnoy A, Castro I, Levay A, Malek TR, Gilboa E. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J Clin Invest 2014; 124:188-97. PMID:24292708 http://dx.doi.org/10.1172/JCI69856
80. Zhou J, Tiemann K, Chomchan P, Alluin J, Swiderski P, Burnett J, Zhang X, Forman S, Chen R, Rossi J. Dual functional BAFF receptor aptamers inhibit ligandinduced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res 2013; 41:4266-83. PMID:23470998 http://dx.doi.org/10.1093/nar/gkt125
81. Hussain AF, Tur MK, Barth S. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing alphavbeta3 integrin. Nucleic Acid Ther 2013; 23:203-12. PMID:23544955
82. Lai WY, Wang WY, Chang YC, Chang CJ, Yang PC, Peck K. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamersiRNA chimeras. Biomaterials 2014; 35:2905-14. PMID:24397988 http://dx.doi.org/10.1016/j.biomaterials.2013.12.054
83. Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, Yang Z. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 2014; 35:3840-50. PMID:24486214
84. Herrmann A, Priceman SJ, Kujawski M, Xin H, Cherryholmes GA, Zhang W, Zhang C, Kowolik C, Forman SJ, Kortylewski M, et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest 2014; 124:2977-87. PMID:24892807 http://dx. doi.org/10.1172/JCI73174
85. Zhang X, Liang H, Tan Y, Wu X, Li S, Shi Y. A U87- EGFRvIII cell-specific aptamer mediates small interfering RNA delivery. Biomed Rep 2014; 2:495-9. PMID:24944794
86. Kim VN. MicroRNA biogenesis: corrdinated cropping and dicing. Nat Rev Mol Cell Biol 2005; 6:376-85. PMID:15852042 http://dx.doi.org/10.1038/nrm1644
87. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-11. PMID:9486653 http://dx.doi.org/10.1038/35888
88. Farazi TA, Spitzer JI, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011; 223:102-15. PMID:21125669
89. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012; 4:143-59. PMID:22351564 http://dx.doi.org/10.1002/emmm.201100209
90. Garofalo M, Condorelli GL, Croce CM, Condorelli G. MicroRNAs as regulators of death receptors signaling. Cell Death Differ 2010; 17:200-8. PMID:19644509 http://dx.doi.org/10.1038/cdd.2009.105
91. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97. PMID:14744438 http://dx.doi.org/10.1016/S0092-8674(04)00045-5
92. Pillai RS, Bhattacharyya SN, Filipowicz W. Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 2007; 17:118-26. PMID:17197185 http://dx.doi.org/10.1016/j.tcb.2006.12.007
93. Jackson RJ, Standart N. How do microRNAs regulate gene expression? Sci STKE 2007; 2007:re1. PMID:17200520
94. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6:857-66. PMID:17060945 http://dx.doi.org/10.1038/nrc1997
95. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in cancer: their role in tumor progression and response to therapy. Curr Mol Med 2012; 12:27-33. PMID:22082479 http://dx.doi.org/10.2174/156652412798376170
96. Kawasaki H, Wadhwa R, Taira K. World of small RNAs: from ribozymes to siRNA and miRNA. Differentiation 2004; 72:58-64. PMID:15066185 http://dx.doi.org/10.1111/j.1432-0436.2004.07202006.x
97. Pontes O, Pikaard CS. siRNA and miRNA processing: new functions for Cajal bodies. Curr Opin Genet Dev 2008; 18:197-203. PMID:18337083 http://dx.doi.org/10.1016/j.gde.2008.01.008
98. Lin SL, Chang D, Ying SY. Asymmetry of intronic pre-miRNA structures in functional RISC assembly. Gene 2005; 356:32-8. PMID:16005165 http://dx.doi.org/10.1016/j.gene.2005.04.036
99. Wu X, Ding B, Gao J, Wang H, Fan W, Wang X, Ye L, Zhang M, Ding X, Liu J, et al. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy. Int J Nanomed 2011; 6:1747-56. PMID:21980237
100. Dai F, Zhang Y, Zhu X, Shan N, Chen Y. Anticancer role of MUC1 aptamer-miR-29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 2012; 7:217-25. PMID:23179556 http://dx.doi.org/10.1007/s11523-012-0236-7
101. Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer Invest 2012; 30:577-82. PMID:22812695 http://dx.doi.org/10.3109/07357907.2012.707265
102. Elmen J, Lindow M, Schutz S, Lawrence M, Petri A, Obad S, Lindholm M, Hedtjärn M, Hansten HF, Berger U, et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452:896-9. PMID:18368051 http://dx.doi.org/10.1038/nature06783
103. Kim JK, Choi KJ, Lee M, Jo MH, Kim S. Molecular imaging of a cancer-targeting theragnostics probe using a nucleolin aptamer- and microRNA-221 molecular beacon-conjugated nanoparticle. Biomaterials 2012; 33:207-17. PMID:21944470 http://dx.doi.org/10.1016/j.biomaterials.2011.09.023
104. Pofahl M, Wengel J, Mayer G. Multifunctional nucleic acids for tumor cell treatment. Nucleic Acid Ther 2014; 24:171-7. PMID:24494617 http://dx. doi.org/10.1089/nat.2013.0472
105. Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp Mol Pathol 2009; 86:151-64. PMID:19454272
106. Falnes PO, Sandvig K. Penetration of protein toxins into cells. Curr Opin Cell Biol 2000; 12:407-13. PMID:10873820 http://dx.doi.org/10.1016/S0955-0674(00)00109-5
107. Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD. Uniformly modified 2’-deoxy-2’-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 1993; 36:831-41. PMID:8464037 http://dx.doi.org/10.1021/jm00059a007
108. Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F. Kinetic characterization of ribonuclease-resistant 2’-modified hammerhead ribozymes. Science 1991; 253:314-7. PMID:1857967 http://dx.doi.org/10.1126/science.1857967
109. Majlessi M, Nelson NC, Becker MM. Advantages of 2’-O-methyl oligoribonucleotides probes for detecting RNA targets. Nucleic Acids Res 1998; 26:2224-9. PMID:9547284 http://dx.doi.org/10.1093/nar/26.9.2224
110. Baker BF, Lot SS, Condon TP, Cheng-Flournoy S, Lesnik EA, Sasmor HM, Bennett CF. 2’-O-(2- Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation oft he ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997; 272:11994-2000. PMID:9115264 http://dx.doi.org/10.1074/jbc.272.18.11994
111. Geary RS, Watanabe TA, Truong L, Freier S, Lesnik EA, Sioufi NB, Sasmor H, Manoharan M, Levin AA. Pharmacokinetic properties of 2’-O-(2-methoxyethyl)- modified oligonucleotide analogs in rats. J Pharmacol Exp Ther 2001; 296:890-7. PMID:11181921
112. Wilds CJ, Damha MJ. 2’-Deoxy-2’-fluoro-b-D-arabinonucleosides and oligonucleotides (2’F-ANA): synthesis and physicochemical studies. Nucleic Acids Res 2000; 28:3625-35. PMID:10982885 http://dx.doi.org/10.1093/nar/28.18.3625
113. Veedu RN, Wengel J. Locked nucleic acid as a novel class of therapeutic agents. RNA Biol 2009; 6: 321-23. PMID:19458498 http://dx.doi.org/10.4161/rna.6.3.8807
114. Veedu RN, Wengel J. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications. Chem Biodivers 2010; 7: 536-42. PMID:20232325 http://dx.doi.org/10.1002/cbdv.200900343
115. Nielson P, Dreiøe LH, Wengel J. Synthesis and evaluation of oligodeoxynucleotides containing acyclicnucleosides. Bioorg Med Chem 1995; 3:19-28. PMID:8612043 http://dx.doi.org/10.1016/0968-0896(94)00143-Q
116. Langkjær N, Pasternak A, Wengel J. UNA (unlocked nucleic acid): A flexible RNA mimc that allows engineering of nucleic acid duplex stability. Bioorg Med Chem 2009; 71:5420-5. PMID:19604699 http://dx.doi.org/10.1016/j.bmc.2009.06.045
117. Herdewijn P. Cyclohexene nucleic acids: serum stable oligonucleotides that activate RNase H and increase duplex stability with complementary RNA. Abstr Pap Am Chem Soc 2001; 221:U155
118. Herdewijn P, De Clercq E. The cyclohexene ring as bioisostere of a furanose ring: synthesis and antiviral activity of cyclohexenyl nucleosides. Bioorg Med Chem Lett 2001; 11:1591-7. PMID:11412988 http://dx.doi.org/10.1016/S0960-894X(01)00270-0
119. Hyrup B, Nielsen P. Peptide Nucleic Acids (PNA): Synthesis, properties and potential applications. Bioorg Med Chem 1996; 4:5-23.http://dx.doi.org/10.1016/0968-0896(95)00171-9
120. Summerton J, Weller D. Morpholino antisense oligomers: design, perparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7:187-95. PMID:9212909 http://dx.doi.org/10.1089/oli.1.1997.7.187
121. Kuwahara M, Sugimoto N. Molecular evolution of functional nucleic acids with chemical modifications. Molecules 2010; 15:5423-44. PMID:20714306 http://dx.doi.org/10.3390/molecules15085423
122. De Mesmaeker A, Häner R, Martin P, Moser HE. Antisense oligonucleotides. Acc Chem Res 1995; 28:366
123. Eaton BE, Pieken WA. Ribonucleosides and RNA. Annu Rev Biochem 1995; 64:837-63. PMID:7574502 http://dx.doi.org/10.1146/annurev. bi.64.070195.004201
124. Sioud M, Sorensen DR. A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat Biotechnol 1998; 16:556-61. PMID:9624687 http://dx.doi.org/10.1038/nbt0698-556
125. Zinnen SP, Domenico K, Wilson M, Dickinson BA, Beaudry A, Mokler V, Daniher AT, Burgin A, Beigelman L. Selection, design, and characterization of a new potentially therapeutic ribozyme. RNA 2002; 8:214-28. PMID:11911367 http://dx.doi.org/10.1017/S1355838202014723
126. Lauridsen LH, Rothnagel JA, Veedu RN. Enzymatic recognition of 2’-modified ribonucleoside 5’-triphosphates: towards the evolution of versatile aptamers. Chembiochem 2012; 13:19-25. PMID:22162282 http://dx.doi.org/10.1002/cbic.201100648
127. Lin Y, Qiu Q, Gill SC, Jayasena SD. Modified RNA sequence pools for in vitro selection. Nucleic Acids Res 1994; 22:5229-34. PMID:7529404 http://dx. doi.org/10.1093/nar/22.24.5229
128. Jellinek D, Green LS, Bell C, Lynott CK, Gill N, Vargeese C, Kirschenheuter G, McGee DP, Abesinghe P, Pieken WA, et al. Potent 20-amino-20-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 1995; 34:11363-72. PMID:7547864 http://dx.doi.org/10.1021/bi00036a009
129. Lin Y, Nieuwlandt D, Magallanez A, Feistner B, Jayasena SD. High-affinity and specific recognition of human thyroid stimulating hormone (hTSH) by in vitro-selected 20-amino-modified RNA. Nucleic Acids Res 1996; 24:3407-14. PMID:8811096 http://dx.doi.org/10.1093/nar/24.17.3407
130. Proske D, Gilch S, Wopfner F, Schatzl HM, Winnacker EL, Famulok M. Prion-protein-specific aptamer reduces PrPSc formation. Chembiochem 2002; 3:717-25. PMID:12203970 http://dx.doi.org/10.1002/1439-7633(20020802)3:8%3c717::AIDCBIC717% 3e3.0.CO;2-C
131. Rusconi CP, Scardino E, Layzer J, Pitoc GA, Ortel TL, Monroe D, Sullenger BA. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature 2002; 419:90-4. PMID:12214238 http://dx. doi.org/10.1038/nature00963
132. Biesecker G, Dihel L, Enney K, Bendele RA. Derivation of RNA aptamer inhibitors of human complement C5. Immunopharmacology 1999; 42:219-30. PMID:10408383 http://dx.doi.org/10.1016/S0162-3109(99)00020-X
133. Burmeister PE, Lewis SD, Silva RF, Preiss JR, Horwitz LR, Pendergrast PS, McCauley TG, Kurz JC, Epstein DM, Wilson C, et al. Direct in vitro selection of a 20-O-methyl aptamer to VEGF. Chem Biol 2005; 12:25-33. PMID:15664512
134. Burmeister PE, Wang C, Killough JR, Lewis SD, Horwitz LR, Ferguson A, Thompson KM, Pendergrast PS, McCauley TG, Kurz M, et al. 20-Deoxy purine, 20-O-methyl pyrimidine (dRmY) aptamers as candidate therapeutics. Oligonucleotides 2006; 16:337-51. PMID:17155909
135. Koshkin AA, Singh SK, Nielsen P, Rajwanshi VK, Kumar R, Meldgaard M, Olsen CE, Wengel J. LNA (Locked Nucelic Acid): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998, 54:3607-3630
136. Singh SK, Koshkin AA, Wengel J, Nielsen P. LNA (locked nucleic acids): synthesis and high-affinity nucleic acid recognition. Chem Commun 1998; 39:455-456.http://dx.doi.org/10.1039/a708608c
137. Obika S, Nanbu D, Hari Y, Andoh JI, Morio KI, Doi T, Imanishi T. Stability and structural features of the duplex containing nucleoside analogues with a fixed N-type conformation, 2’-O,4’-C-methyleneribonucleotieds. Tetrahedron Lett. 1998; 39:5401.http://dx. doi.org/10.1016/S0040-4039(98)01084-3
138. Veedu RN, Vester B, Wengel J. Polymerase chain reaction and transcription using locked nucleic acid nucleotide triphosphates. J Am Chem Soc 2008; 130:8124-5. PMID:18533656 http://dx.doi.org/10.1021/ja801389n
139. Veedu RN, Vester B, Wengel J. Enzymatic incorporation of LNA nucleotides into DNA strands. Chem- BioChem 2007; 8:490-2. PMID:17315250 http:// dx.doi.org/10.1002/cbic.200600501
140. Veedu RN, Vester B, Wengel J. Efficient Enzymatic Synthesis of LNA-modified DNA duplexes using KOD DNA polymerase. Org Biomol Chem 2009; 7:1404-9. PMID:19300826 http://dx.doi.org/10.1039/b819946a
141. Veedu RN, Vester B, Wengel J. In Vitro incorporation of Locked Nucleic Acids. Nucleosides Nucleotides Nucleic Acids 2007; 26:1207. PMID:18058567 http://dx.doi.org/10.1080/15257770701527844
142. Veedu RN, Wengel J. Locked nucleic acid nucleoside triphosphates and polymerases: On the way towards evolution of LNA aptamers. Mol Biosyst 2009; 5: 787-92. PMID:19603111 http://dx.doi.org/10.1039/b905513b
143. Doessing H, Hansen L, Veedu RN, Wengel J, Vester B. Amplification and Re-Generation of LNA-Modified Libraries. Molecules 2012; 17: 13087-97. PMID:23128088 http://dx.doi.org/10.3390/ molecules171113087
144. Crouzier L, Dubois C, Edwards SL, Lauridsen LH, Wengel J, Veedu RN. Efficient Reverse Transcription Using Locked Nucleic Acid Nucleotides towards the Evolution of Nuclease Resistant RNA Aptamers. Plos One 2012; 7: e35990. PMID:22558297
145. Kasahara Y, Irisawa Y, Ozaki H, Obika S, Kuwahara M. 2’,4’-BNA/LNA aptamers: CE-SELEX using a DNAbased library of full-length 2’-O,4’-C-methylenebridged/ linked bicyclic ribonucleotides. Bioorg Med Chem Lett 2013; 23:1288-92. PMID:23374873 http://dx.doi.org/10.1016/j.bmcl.2012.12.093
146. Kuwahara M, Obika S. In vitro selection of BNA (LNA) aptamers. Artif DNA PNA XNA 2013; 4:39-48. PMID:24044051 http://dx.doi.org/10.4161/adna.25786
147. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 2003; 31:3406-15. PMID:12824337
148. Kushner DM, Silverman RH. Antisense cancer therapy: the state of the science. Curr Oncol Rep 2000; 2:23-30. PMID:11122821 http://dx.doi.org/10.1007/s11912-000-0007-y
149. Perry CM, Balfour JA. Fomivirsen. Drugs 1999; 57:375-80; discussion 81 PMID:10193689 http:// dx.doi.org/10.2165/00003495-199957030-00010